Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1812.1, up 1.6% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.18% on the day, quoting at 25360.65. The Sensex is at 83104.96, down 0.16%. Glenmark Pharmaceuticals Ltd has gained around 14.34% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 3.4% in last one month and is currently quoting at 22204.25, up 0.79% on the day. The volume in the stock stood at 3.99 lakh shares today, compared to the daily average of 10.37 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 1821.7, up 1.76% on the day. Glenmark Pharmaceuticals Ltd is up 35.42% in last one year as compared to a 4.26% jump in NIFTY and a 9.41% jump in the Nifty Pharma index.
The PE of the stock is 28.84 based on TTM earnings ending March 25.
Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1773.3, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.22% on the day, quoting at 25484.65. The Sensex is at 83437.68, down 0.31%. Glenmark Pharmaceuticals Ltd has gained around 17.13% in last one month.
Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 3.58% in last one month and is currently quoting at 22041.25, up 0.35% on the day. The volume in the stock stood at 2.49 lakh shares today, compared to the daily average of 11.89 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 1779.6, up 0.78% on the day. Glenmark Pharmaceuticals Ltd is up 38.34% in last one year as compared to a 4.93% jump in NIFTY and a 11.06% jump in the Nifty Pharma index.
The PE of the stock is 28.38 based on TTM earnings ending March 25.
Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA® (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO).
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. It is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as monotherapy.
This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio. NSCLC is the most common type of lung cancer, representing over 80% of all lung cancer cases. Similarly, ESCC is the most common histological subtype of esophageal cancer in India. TEVIMBRA caters to the needs of this significant patient population by offering a differentiated and proven treatment option for these cancers.
TEVIMBRA is approved and marketed in multiple leading global markets including the United States, European Union, Australia and China. Designed to selectively bind to PD-1 receptors, TEVIMBRA restores T-cell function while minimizing off-target immune suppression and has demonstrated robust efficacy with a favorable safety profile across diverse solid tumor types in multiple pivotal Phase 3 studies and through a comprehensive global clinical development program.